Abstract Chronic kidney disease (CKD) has become a significant public health concern, as it is associated with substantial morbidity. Prior research has evaluated multiple novel CKD biomarkers to supplement serum creatinine and proteinuria. The ultimate goal of this research is to find biomarkers that can be used to accurately predict CKD progression and to better time outpatient follow-up, and referral for transplant. Also, an optimal panel of biomarkers can augment the predictive value of proteinuria and serum creatinine by enriching patient enrollment in clinical trials. In this review, we discuss salient findings on 12 candidate plasma and urine biomarkers and their reported association with CKD. We explore the common pathways of CKD progression and the pathophysiologic processes of tubulointerstitial injury, inflammation, repair, and fibrosis that are potentially classified by specific biomarkers. We describe both pediatric and adult findings and highlight the paucity of pediatric research in CKD progression. It will be important for cohorts with longitudinal follow-up to evaluate these CKD biomarkers for potential use in pediatric clinical trials and routine CKD management.
Introduction
Chronic kidney disease (CKD) in children is characterized by kidney damage or a decrease in glomerular filtration rate (GFR) lasting for at least 3 months [1] . CKD in children is associated with high morbidity and mortality [2] . Additionally, pediatric CKD strikes during a vulnerable time and negatively impacts a child's growth and development. Despite poor outcomes, there has been only one clinical trial demonstrating efficacy in limiting CKD progression in children [3] . New treatments to slow CKD progression in children are sorely needed.
A barrier to developing new CKD therapies is the limitations of our conventional biomarkers, proteinuria and serum creatinine. Although elevated serum creatinine and proteinuria are the most frequently utilized biomarkers of CKD, creatinine and proteinuria increase relatively late in the course of kidney damage in CKD [4] . Children with underlying structural changes in the kidney may not have changes in serum creatinine due to the underlying 'renal reserve' -the capacity of nephrons to maintain GFR by hyperfiltration and compensatory hypertrophy until substantial injury has occurred. Serum creatinine levels may be affected by the race, sex, muscle mass, hydration status, and medications; hence, changes in creatinine may not represent true changes in kidney function [5] . Additionally, the kidney may undergo significant structural changes in the glomerulus and tubulointerstitial compartments before proteinuria is measureable. Proteinuria and serum creatinine only explain 32% of the variability of measured GFR decline among children in the Chronic Kidney Disease in Children (CKiD) study [6] . Additional biomarkers of CKD progression may capture the variability left unexplained by our traditional CKD biomarkers. An ideal biomarker should be non-invasive, easy to measure, sensitive, and serve to indicate targeted therapies likely to be effective [7] .
A biomarker is any molecular, histologic, radiographic, and physiologic characteristic that can be measured as an indicator or predictor of a normal biologic process, pathologic process, or response to a therapeutic intervention [8] . The Food and Drug Administration-National Institute of Health Biomarker Working Group has used the terms diagnostic, prognostic, predictive, monitoring, pharmacodynamics/response, safety, or susceptibility/risk to classify different types of biomarkers [9] . A prognostic biomarker is used to identify the likelihood of a clinical event, disease recurrence, or progression of a disease [9] . In children with CKD, a prognostic biomarker may allow us to identify patients at high risk of CKD progression. Prognostic biomarkers may be useful to enhance enrollment in pediatric CKD clinical trials and improve the efficiency of trial design.
Although there are several causes of CKD in children, there is one common pathway of CKD progression involving kidney injury, maladaptive repair, and progressive nephron loss [10] . This is supported by common histologic findings in advanced CKD regardless of primary disease [11] . Our overall conceptual model is presented in Fig. 1 , with the associated putative pathophysiologic process that may yield biomarkers [13] . CKD progression is strongly influenced by these multiple pathophysiologic processes including systemic and glomerular hypertension, proteinuria, tubulointerstitial injury and fibrosis, inflammation, and capacity for renal repair [14] . Novel biomarkers can be leveraged to characterize these various mechanisms involved in CKD progression. A better understanding of the diverse proteins and pathways that predict renal outcomes may augment clinical research efforts and lead to the development of therapies to limit CKD progression.
We summarized the existing literature on candidate biomarkers of CKD and CKD progression with an emphasis on research in children. We categorized biomarkers by the associated pathophysiologic pathways. We searched the PubMed database to identify a comprehensive list of research studies that evaluated biomarkers of CKD. Search terms included 'biomarker' or 'biologic marker' in conjunction with 'CKD', 'CKD progression', 'Chronic renal insufficiency', or 'Chronic renal failure'. Studies were eligible for inclusion if they were published in the English language from January 1985 onward, produced [12] quantitative statistics, and were retrospective or prospective cohort studies, case-control studies, or randomized controlled trials. Studies were excluded if they reported on fewer than 20 patients at the time of follow-up. We focused on novel biomarkers of CKD that had been evaluated in both pediatric and adult populations. We found 794 possible articles, 719 in adult cohorts, and 75 of that were focused on children. Full text review identified a total of 56 studies for inclusion, 39 in adults and 17 in children. Table 1 lists specific biomarkers in categories of putative pathways. The results of prior pediatric research on biomarkers of CKD are summarized in Table 2 . Our search revealed that there is a relative dearth of information on biomarkers in pediatric CKD. Virtually all the studies published in children were crosssectional, and only one had more than 100 pediatric patients studied. Much of the existing knowledge concerning biomarkers is therefore derived from studies in adults, who have a very different set of pathologies leading to CKD.
Biomarkers of tubulointerstitial injury and fibrosis
Regardless of the primary cause of CKD, tubulointerstitial disease is an important step that leads to nephron loss and is an accurate predictor of progression to end stage renal disease (ESRD) [32] . Damage in the tubulointerstitium develops as a consequence of a number of processes involving the tubular lumen, tubular epithelial cells, peritubular capillaries, interstitial cells, and extracellular matrix. In response to injury, tubular epithelial cells undergo a complex series of structural and functional changes and produce cytokines, which in turn lead to interstitial inflammation and fibrosis [33] . Knowledge of the mechanisms and interactions leading to these changes has increased exponentially over the past decade, and has defined a number of new inflammatory mediators and targets for treatment. Biomarkers of tubulointerstitial injury as well as the subsequent fibrosis may serve as appropriate markers of prior and ongoing CKD progression [34] [35] [36] .
Biomarkers of tubular injury
Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is a protein produced by neutrophils and kidney tubular cells with increased synthesis occurring in states of tubular injury. The production of uNGAL in the distal segments of the nephron is upregulated in patients with CKD. It has been established as a sensitive marker of early renal tubular injury in children [37] . uNGAL has also been shown to be a predictor of disease severity, as demonstrated in two pediatric studies of childhood lupus and hemolytic uremic syndrome [15, 16] . In a study by Smith et al. including 158 adults with stage 3 or 4 CKD, baseline uNGAL was associated with a rapid decline in renal function within 1 year and ESRD within 2 years [34] . Liu et al. assessed the performance of baseline uNGAL for predicting GFR decline in 3386 adults in the Chronic Renal Insufficiency Cohort Study [36] . At 3 years of follow-up, patients with the highest quintile of uNGAL were 70% more likely to experience a 50% reduction in estimated GFR (eGFR) or ESRD. However, when controlled for known CKD progression risk factors, including eGFR and proteinuria, uNGAL did not significantly improve risk prediction of progression outcomes. Pre-clinical as well as human studies of kidney disease have shown that uNGAL decreases after effective therapeutic interventions [38, 39] . Urinary interleukin-18 (IL-18) is an inflammatory cytokine produced by macrophages and proximal tubular cells in response to injury. Zubowska et al. studied the role of IL-18 in identifying subclinical renal dysfunction in 85 pediatric oncology patients [17] . At 4.6 years of follow-up, nephrectomy and previous exposure to chemotherapy were associated with significantly higher levels of urinary IL-18. In 153 transplant recipients, higher levels of urinary IL-18 measured on the first post-transplant day predicted a faster decline in renal allograft function at 1-year post-transplant [40] . In a cohort of 908 HIVinfected patients, baseline IL-18 was associated with a decline in kidney function and higher mortality, even when controlled for eGFR and albuminuria [41, 42] .
Urinary and blood kidney injury molecule-1 (KIM-1) is a tubular protein that is undetectable in a healthy kidney but is markedly elevated with renal injury [43] . Urinary KIM-1 has been shown to be a marker of disease severity in children with nephrotic syndrome as levels were higher in steroid-resistant nephrotic syndrome as compared to steroid-dependent nephrotic syndrome [18] . Children with type 1 diabetes and without albuminuria had higher levels of urinary KIM-1 when compared to non-diabetic controls [19] . Urinary KIM-1 expression was significantly increased on kidney biopsies within areas of fibrosis or inflammation [44] . Urine KIM-1 was also found to be elevated in all patients with kidney disease except those with minimal change disease [44] . In a study of 145 renal transplant patients, compared to the first tertile, the highest tertile of urine KIM-1 predicted future GFR decline [47] . Urinary epidermal growth factor (EGF) is implicated in tubular cell repair and renal recovery after tubulointerstitial injury. EGF is implicated in key pathways of CKD progression across several etiologies. EGF has a high degree of tissue specificity as it is derived from the ascending loop of Henle and distal convoluted tubule. uEGF has been measured in a cohort of children with CKD and found to have a strong correlation with GFR [20] . In three independent cohorts of glomerular disease, the addition of uEGF to a conventional model including eGFR and albuminuria, prediction of CKD progression was improved [48] .
Biomarkers of interstitial fibrosis
Blood matrix metalloproteinase-9 (MMP-9) is a protease responsible for degrading extracellular matrix and is a candidate biomarker of renal fibrosis, cardiovascular outcomes, and progressive renal injury [49] . In children with FSGS, urinary MMP-9 was found to be substantially higher than children with MCNS and children without kidney disease [21] . In a cohort of pediatric patients with CKD, plasma MMP-9 was significantly higher in children with CKD compared to children without CKD [22] . In a cohort of 251 adults, elevated plasma MMP-9 predicted CKD progression after 8.5 years of follow-up with a hazard ratio of 4.7 (95% CI: 2.1-10.4) [50] .
Blood transforming growth factor beta 1 (TGF-β 1 ) promotes cell migration, inflammation, extra-cellular matrix formation, and irreversible tissue damage. TGF-β 1 is released from tubular epithelial cells, fibroblasts, and infiltrating inflammatory cells. In children with idiopathic nephrotic syndrome, urinary TGF-β 1 was higher in patients with FSGS as compared to minimal change disease [26] . Children with obstructive uropathy had higher urinary TGF-β 1 than children with non-obstructive uropathy [27] . In a study of 281 patients with type 2 diabetes, high TGF-β 1 was a strong predictor of doubling of serum creatinine and ESRD. The cumulative risk of doubling of serum creatinine and ESRD in the fourth quartile of TGF-β 1 was 8.4 times that of the lowest quartile [51] .
Blood bone morphogenetic protein-7 (BMP-7) is a TGF-β 1 antagonist with anti-fibrotic and anti-inflammatory properties. Blood BMP-7 was higher in pediatric CKD patients as compared to controls [28] . Recombinant human BMP-7 infusion decreases fibrosis and inflammation in models of obstructive uropathy and slows GFR decline in mouse models of lupus nephritis and Goodpasture's disease [52, 53] . In a study of 281 patients with type 2 diabetes, low levels of BMP-7 were a strong predictor of doubling of serum creatinine and ESRD. The cumulative risk of renal endpoints in the lowest quartile of BMP-7 was 24 times that of the highest quartile [51] .
Urinary procollagen III N-terminal propeptide (PIIINP) is a propeptide byproduct of collagen 3 deposition and is used as a marker of renal fibrosis [54] . In a study on 29 children with UPJ obstruction and 30 healthy controls, urine PIIINP levels were found to be associated with worsening obstruction [23] . Urine PIIINP has been found to correlate with interstitial fibrosis on the renal biopsy of CKD patients [55] . Additionally, in a study on renal transplant recipients, urine PIIINP was found to be a marker of CKD progression [56] . In a study evaluating 958 adults in the Cardiovascular Health Study, each doubling of urine PIIINP was associated with a 22% higher odds of CKD progression [57] .
Inflammatory biomarkers
A complex interaction between cytokines and immunologic cells play an essential role in mediating inflammation. Chronic low-grade inflammation appears to play an important role in the initiation and progression of CKD. Inflammation is due to the initial, continuous, or recurrent kidney injury from the primary disease, hypoalbuminemia, and reduced clearance of cytokines and metabolites. Furthermore, proteinuria, which is very common in CKD, appears to contribute to renal injury and a pro-inflammatory state. Several candidate inflammatory biomarkers have been hypothesized to not only predict GFR decline but also contribute directly to renal injury and CKD progression [58, 59] .
Blood soluble urokinase-type plasminogen activator receptor (suPAR) is directly involved in the regulation of cell adhesion and migration through binding of integrins. suPAR interferes with podocyte migration, induces apoptosis, and is implicated in the pathogenesis of kidney disease. Wei et al. studied 70 children and adults with biopsy-proven FSGS and found that a reduction of circulating suPAR concentration was positively associated with complete remission as well as a reduction of proteinuria [30] . This research suggests that suPAR may be a biomarker of future decline in GFR, as proteinuria is an established risk factor for CKD progression. Additionally, plasma suPAR concentration was higher in pediatric patients with steroid-resistant nephrotic syndrome versus steroid-sensitive nephrotic syndrome (3744.1 ± 2226.0 vs. 2153.5 ± 1167.0, p < 0.05) [31] . In a cohort of 3683 adults from the Emory Cardiovascular Biobank, higher plasma suPAR predicted incident CKD such that the patients with the lowest quartile of suPAR levels had an annual eGFR change of −0.9 ml/min/1.73 m 2 compared with −4.2 ml/min/ 1.73 m 2 in the highest quartile [59] .
Blood tumor necrosis factor receptor-1 and -2 (TNFR1 and TNFR2). Tumor necrosis factor (TNF) is a central mediator of inflammation, cell proliferation, cellular differentiation, and cell death [60] . TNF exerts its effect on intracellular signaling pathways through interaction with two cell membrane receptors, TNFR1 and TNFR2. A pediatric study implicated the TNF pathway in the recurrence of FSGS and showed improvement in proteinuria after TNF antibodies were administered [61] . Serum TNFR1 was studied in children with vesico-ureteric reflux and higher levels were able to distinguish children with reflux nephropathy versus those without [29] . Patel et al. studied 25 children with systemic lupus erythematous and 20 healthy controls and displayed that TNFR2 is higher in children with SLE, and highest in children with lupus nephritis [47] . The TNF pathway has been implicated in several causes of CKD including diabetic nephropathy, obstructive nephropathy, lupus nephritis, nondiabetic CKD, and ANCA-induced nephritis [60, [62] [63] [64] . In a study of 410 patients with type 2 diabetes, TNFR1 was a strong predictor of progression to ESRD [58] . The cumulative risk of ESRD in the fourth quartile of TNFR1 was 54% after 12 years vs. 3% for all other patients. The hazard ratios for ESRD show that non-proteinuric patients in the fourth quartile of TNFR1 are over seven times more likely to progress to ESRD than all other patients. TNFR1 and TNFR2 were also found to predict incident stage 3 CKD in type 1 diabetics [35] . Animal models of obstructive uropathy, a common cause of CKD in children, showed that renal tubular TNFR2 was markedly increased [65] . Furthermore, TNFR2-deficient mice were found to have significantly less tubulointerstitial fibrosis in models of obstructive uropathy [66] .
Urinary monocyte chemoattractant protein-1 (MCP-1) is a chemokine that recruits monocytes and promotes their transformation into macrophages. Urinary levels of MCP-1 were significantly higher in pediatric CKD patients compared to controls. Additionally, patients with glomerular disease had higher MCP-1 as compared with non-glomerular disease patients [24] . Urinary MCP-1 was identified as a marker of kidney disease severity in children with SLE [25] . In animal models of lupus nephritis, MCP-1 antagonists have limited kidney disease progression, suggesting MCP-1 has a primary role in disease activity [67] . In patients with diabetic nephropathy, urine MCP-1 levels correlate with kidney macrophage accumulation, fibrosis, and GFR decline [68, 69] . Urine MCP-1 levels also correlate with the rate of decline in GFR in nondiabetic CKD [70] . MCP-1 has been identified as a potential therapeutic target in patients with CKD with multiple ongoing MCP-1 inhibitor trials [71] .
Conclusions
Numerous longitudinal studies in adults describe the association between novel biomarkers and CKD progression. However, none of these biomarkers has yet been qualified by the FDA for clinical use. In the field of pediatric medicine, studies in CKD biomarkers are mostly restricted to crosssectional analyses, and only six studies have included more than 50 children. CKD biomarkers that more precisely identify chronic injury and act as surrogates of CKD progression are sought for advancing pediatric clinical trials. In particular, if prognostic biomarkers could be identified, strategies to enrich recruited subjects at high risk of meeting study endpoints could be employed, which may decrease the cost and sample size necessary to identify effective treatments. In the clinical setting, these biomarkers may help to predict response to therapy and to predict long-term outcomes in patients with CKD. When using biomarkers of therapeutic response, consideration should be given to biomarkers that correlate with a proposed therapy, depending on the targeted pathway of CKD progression. Although there is a paucity of treatments for pediatric CKD progression, clinical trials in adult CKD participants targeting inflammatory, hemodynamic, or fibrotic pathways may soon yield candidate therapies that can be trialed in children [72] .
Importantly, novel biomarkers must first be shown to enhance prediction of CKD progression when added to a model that includes serum creatinine and proteinuria. Liu et al. demonstrated that urine NGAL predicted CKD progression, but did not significantly improve upon a clinical model of CKD risk factors including eGFR and proteinuria [36] . However, TNFR1 and TNFR2 were found to have a strong association with progression to ESRD even after controlling for albuminuria and eGFR [58] .
Novel biomarkers of CKD may be more readily identified studying pediatric cohorts as adults have more comorbidities and concurrent disease, which may affect biomarker concentrations and modify CKD progression. Additionally, CKD in children is most commonly caused by isolated congenital anomalies of the kidney or urinary tract (CAKUT), which is not a systemic multi-organ disease such as diabetic nephropathy. The CAKUT model of CKD progression may be easier to characterize with less systemic and inflammatory influences. With additional research we will learn whether these novel biomarkers have an associative relationship with GFR decline or whether they also have true mechanistic roles in CKD progression.
Novel biomarkers may identify children with the earliest stages of injury and repair, before proteinuria or serum creatinine identifies irreversible injury and nephron loss. Since CKD progression involves multiple processes in the kidney, it is unlikely that one biomarker will best predict GFR decline. It is likely that panels of biomarkers which leverage the additive properties of each individual biomarker will be the most useful clinical tools in identifying risk for CKD progression in children. A panel of biomarkers that represent the multifactorial pathophysiologic mechanisms leading to CKD progression including tubulointerstitial injury, fibrosis, inflammation, and repair may prove useful for predicting GFR decline in children. Further pediatric research, preferably prospective longitudinal studies, will be needed to assess whether these novel biomarkers can be used to predict CKD progression. In addition to research applications, novel biomarkers could help guide the prognosis given to families as well as the timing of follow-up visits and referral for transplant evaluation. The application of novel biomarkers has the potential to revolutionize clinical decision-making as well as clinical trials of CKD progression.
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